# Biohaven

Source: https://onco.cc/companies/biohaven/  
OnCo record `biohaven` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A listed US drug company working across several diseases. In cancer it is testing two antibody-drug conjugates, drugs that carry a toxin to cancer cells, in early trials for advanced solid tumours including bladder cancer.

## Summary

Biohaven Ltd. describes itself as working in immunology, obesity, neuroscience and oncology. Its oncology pipeline lists two antibody-drug conjugates in Phase 1b: BHV-1510, a Trop2-directed ADC tested alone and with a PD-1 antibody in advanced or metastatic epithelial tumours (NCT06384807, where it is named as previously PBI-410, with cemiplimab), and BHV-1530, an FGFR3-directed ADC for urothelial cancer and other tumours (NCT06874335, also listed as AMB302, alone and with cemiplimab). The rest of its pipeline covers extracellular protein degraders, Kv7 ion channel modulators, myostatin/activin inhibition, TRPM3 antagonism and TYK2/JAK1 inhibition. Biohaven Ltd. trades on the NYSE under BHVN according to its SEC filings.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Biohaven Ltd.; Biohaven Ltd
- HQ: New Haven, CT
- Type: biotech
- Website: https://www.biohaven.com/
- Ticker: NYSE: BHVN

## Notes

- RA Capital's page records an acquisition announced in 2022 alongside the original IPO; that refers to the earlier Biohaven company, and this record covers the current Biohaven Ltd. (SEC former name Biohaven Research Ltd., 2022). The 2022 transaction itself was not read from a primary source and is not described here.
- Founding year of Biohaven Ltd. not stated on pages read.
- BHV-1530 has no product record yet (drafted in products file); NCT06874335 is not yet a trial record in OnCo.

## Sources

- Official website: https://www.biohaven.com/
- Pipeline page: https://www.biohaven.com/pipeline/
- ClinicalTrials.gov NCT06384807: https://clinicaltrials.gov/study/NCT06384807
- ClinicalTrials.gov NCT06874335: https://clinicaltrials.gov/study/NCT06874335
- SEC EDGAR filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001935979
- RA Capital portfolio entry: https://www.racap.com/portfolio/biohaven

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [FGFR3](https://onco.cc/targets/fgfr3-receptor/), [TROP2](https://onco.cc/targets/trop2/)
- drugs: [BHV-1510](https://onco.cc/drugs/bhv-1510/), [BHV-1530](https://onco.cc/drugs/bhv-1530/)
- trials: [A Phase 1 Study of BHV-1530 in Advanced Solid Tumors](https://onco.cc/trials/nct06874335/), [A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors](https://onco.cc/trials/nct06384807/)
- companies: [RA Capital Management](https://onco.cc/companies/ra-capital/)

---
JSON: https://onco.cc/api/v1/entities/biohaven.json